Effect of peptide hormone CJC-1295 in your body workout

CJC-1295 is basically a peptide hormone that acts similar to growth hormone releasing hormones (GHRH). It is beneficial to athletes because it can bioconjugate with circulating albumin and increase the time it can be used for medical purposes. It achieves this by preventing degradation of its amino acids. With a single dose, it can remain in the body for quite a few days and can cause the growth hormone to be released many times per day. This reduces the frequency of injections needed.CJC-1295 increases the production of growth hormone as well as IGF-1 – which has anabolic effects in adults. However, it does not increase the levels of prolactin – high levels of which can create impotence and mental health problems in men. By increasing these two hormones, it enhances protein production in the body, which in turn, boosts muscle mass. It also induces lipolysis – the breakdown of fat tissue, boosts recovery from injuries, increases bone density, and also reduces aging factors like skin wrinkles. It can also stimulate cell growth, due to which it can be used to treat withered tissue or organs.

CJC-1295 is also known by the names of Modified GRF 1-29, Mod GRF 1-29, CJC-1295 without DAC (DAC stands for Drug Affinity Complex) and also by its chemical name tetrasubstituted GRF (1-29). This variety of names makes it difficult for the average consumer to select or even research upon this compound. Since some manufacturers list all of its names and others list only one, it also becomes very confusing. However, there is a reason for this wide variety of names.

The original GRF (1-29) has a half-life of about 30 minutes. Half-life means the time within which half of the hormone administered will be destroyed within the body. This short half-life is due to the fact that the compound is highly unstable and breaks down soon. To increase its stability and to make it last longer, it was modified by adding 4 amino acids in its structure. This gave it the name Modified GRF (1-29) or Mod GRF 1-29. It was originally invented by DatBtrue. The portion of the molecule that actually stimulates the growth hormone secretion is found in the chain of 29 amino acids, so it is named GRF (1-29). This chemical also produces slow-wave sleep.

However, both the original GRF (1-29) and the Mod GRF 1-29 required frequent dosages. So a new compound called CJC-1295 was created which was far more stable. This compound was made by adding Lysine – which is a non-peptide, and is also called Drug Affinity Complex or DAC. Since the original Mod GRF 1-29 does not contain DAC, it is named as CJC-1295 without DAC. However, the actual CJC-1295 is not only difficult, but also very expensive to produce. This is why it is not produced or used extensively. The Mod GRF 1-29 is far easier and cheaper to produce. CJC-1295 acts for much longer than pure GRF. It acts on the pituitary gland and keeps stimulating the release of growth hormone in pulses. The reason why it acts in pulses is because the axis of the human growth hormone controls how much of the hormone can remain in the body at a time. This maintains the homeostatic environment in the body.

The DAC technology in the CJC-1295 enables the compound to bind itself covalently with any circulating albumin, after it has been administered through a subcutaneous injection. However, the reason why the half-life could be extended from a few minutes to several days is more profound. The reactive group in the CJC-1295 binds to a peptide through bioconjugation. The peptide then finds a neucleophilic unit within the blood and reacts with it in order to create a firmer bond.

When using any GHRH, it should always be remembered that positive results cannot be achieved overnight. These compounds act steadily over time, and the best results can be achieved slowly, and with a nutritious diet and a proper exercise regime. Also, these peptides are not sex-specific, so they do not have any androgenic effects. They can be used by women in the same dosages that men do. Mod GRF 1-29 and CJC-1295 are still being researched. As such, they are not yet medically utilized or approved. Though some firm protocols for the use of these peptides have been developed, the dosage of the compound is not yet medically confirmed. In a study conducted by researchers on 21 to 61 year-old subjects, it was found that depending on the dose, the concentrations of the growth hormone increased to up to 10 times for at least 6 days. Also, the concentration of IGF-1 increased to up to 3 times for 9 to 11 days.

CJC-1295 and Mod GRF 1-29 are administered in micrograms (mcg) rather than milligrams (mg) – the unit of administration of other steroids and performance-enhancing drugs. It has also been found that a 100mcg dose is enough to fully saturate the receptors in the anterior pituitary. This is called the saturation dose. After a dose of 100mcg has been administered, the subsequent dosages will achieve only half the effect.For example, if 100mcg more were to be administered after the first 100mcg (making the effective dose of 200mcg), then the second dose will achieve only 50% of what the first dose already did. A 100mcg more (making a total of 300mcg) will achieve only 25% more of the initial dose. This implies that, in order to increase the effect of the compound, only a little more of it can be successfully administered after the saturation dose.